RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Feb 19, 2013 - 1:22:36 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
GW researcher receives grant to study treatment and cause of cardiovascular disease in HIV patients

Oct 1, 2012 - 4:00:00 AM
If we see these mice have low levels of HDL, compared to the control group of mice, it will prove that Nef can influence HDL levels, said Bukrinsky. If we prove our hypothesis, we find the mechanisms of how HIV does that and we will be able to treat the condition. The direct application would be drugs that target Nef and prevent its effects on this HDL metabolism. That is the ultimate goal.

 
[RxPG] In 1980, men and women who were diagnosed with the human immunodeficiency virus (HIV) had little to no hope of living long, full lives. Thanks to advances in science and medicine, this is no longer the case. HIV patients now live a near-normal lifespan. However, as patients live longer, new medical issues arise. Michael I. Bukrinsky, M.D., Ph.D., professor of microbiology, immunology, and tropical medicine and professor of biochemistry and molecular biology at the George Washington University School of Medicine and Health Sciences, saw that cardiovascular disease was becoming a major clinical problem in HIV patients. The National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute awarded him a grant to study the issue further. His research on this topic is in its third year, and in August, he received a supplement of $156,292 to continue his efforts to find a way to help HIV patients better understand treatments for health issues that may arise as they age.

His project, titled HIV Disease and Impairment of High Density Lipoprotein Metabolism, will look into the mechanisms of atherosclerosis in HIV-infected patients. One question that will be addressed is whether, as many believe, cardiovascular issues in HIV patients are due to the adverse effects of pro-longed use of toxic anti-HIV drugs. Bukrinsky believes that while drugs may contribute to this problem, HIV infection itself may also be a significant factor.

The belief has been, that the reason for cardiovascular issues was not HIV itself, but drugs used to treat HIV, said Bukrinsky. We are trying to prove that though drugs may contribute to this problem, HIV itself is actually a very significant risk factor. These two factors work together to infuse this atherosclerotic change in patients.

Bukrinsky has been studying the effects of HIV infection on metabolism and the function of high-density lipoprotein (HDL), in hopes of finding a way to target and treat cardiovascular disease in these patients. The supplemental funding will be used to establish an animal model that will recreate the events researchers think are happening in HIV patients. Bukrinsky believes that cells infected with HIV are secreting viral protein called Nef into the blood stream that then cause other, uninfected cells to produce lower HDL levels. To study whether this is occurring, the transgenic mice will produce this protein from their cells, which will enter their bloodstream. Bukrinsky and his research team will then study what affect this has on HDL to either prove or disprove their hypothesis.

If we see these mice have low levels of HDL, compared to the control group of mice, it will prove that Nef can influence HDL levels, said Bukrinsky. If we prove our hypothesis, we find the mechanisms of how HIV does that and we will be able to treat the condition. The direct application would be drugs that target Nef and prevent its effects on this HDL metabolism. That is the ultimate goal.

To arrange an interview with Dr. Bukrinsky, please contact Lisa Anderson at 202-994-3121 or



Related Latest Research News
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Book explores undiscovered economics of everyday life

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)